Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Crizotinib + Pazopanib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Crizotinib | Xalkori | PF-02341066 | ALK Inhibitor 33 BCR-ABL Inhibitor 32 MET Inhibitor 59 RON Inhibitor 11 ROS1 Inhibitor 22 | Xalkori (crizotinib) inhibits ALK kinase, ALK fusion proteins, c-Met, ROS1 fusion proteins, and MST1R (RON), resulting in growth inhibition of tumor cells (PMID: 26951079, PMID: 22617245). Xalkori (crizotinib) is FDA approved for use in patients with ALK- or ROS1-positive (rearrangements and fusions) metastatic non-small cell lung cancer, in pediatric patients 1 year and older and young adults with relapsed or refractory, ALK-positive systemic anaplastic large cell lymphoma, and in adult and pediatric patients 1 year and older with ALK-positive, unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (FDA.gov). |
Pazopanib | Votrient | GW-786034 | FGFR1 Inhibitor 28 FGFR2 Inhibitor 24 FGFR3 Inhibitor 21 KIT Inhibitor 57 PDGFR Inhibitor (Pan) 30 VEGFR Inhibitor (Pan) 36 | Votrient (pazopanib) inhibits VEGFR-1, -2 and -3, KIT, and PDGFR, and FGFR1, 2, and 3, leading to decreased tumor angiogenesis and growth (PMID: 17620431, PMID: 23786770). Votrient (pazopanib) is approved for renal cell carcinoma and soft tissue sarcoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK R1209Q | colon cancer | predicted - sensitive | Crizotinib + Pazopanib | Case Reports/Case Series | Actionable | In a Phase I trial, Xalkori (crizotinib) and Votrient (pazopanib) combination treatment resulted in a partial response in a patient with colon cancer harboring ALK R1209Q (PMID: 33994796; NCT01548144). | 33994796 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01548144 | Phase I | Crizotinib + Pazopanib Crizotinib + Pemetrexed Disodium Pazopanib + Pemetrexed Disodium Crizotinib + Pazopanib + Pemetrexed Disodium | Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer | Terminated | USA | 0 |